New Therapeutic Entities

Articles

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.